Get the Stockscreener App
2.73
7.48%
0.19
Pre-market:
2.80
0.07
+2.56%
Vistagen Therapeutics Inc stock is traded at $2.73, with a volume of 110.26K.
It is up +7.48% in the last 24 hours and up +39.29% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$2.54
Open:
$2.661
24h Volume:
110.26K
Relative Volume:
0.54
Market Cap:
$79.60M
Revenue:
$875.70K
Net Income/Loss:
$-39.57M
P/E Ratio:
-2.0338
EPS:
-1.3423
Net Cash Flow:
$-33.65M
1W Performance:
+10.53%
1M Performance:
+39.29%
6M Performance:
-8.08%
1Y Performance:
-30.71%
1-Day Range:
$2.64
$2.7495
1-Week Range:
$2.40
$2.7495
52-Week Range:
$1.90
$3.94
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.73 | 74.06M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
What analysts say about Vistagen Therapeutics Inc. stockExceptional earning trajectories - Autocar Professional
Is Vistagen Therapeutics Inc. a good long term investmentTremendous financial leverage - jammulinksnews.com
What drives Vistagen Therapeutics Inc. stock priceHigh-velocity capital appreciation - jammulinksnews.com
Vistagen Therapeutics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What makes Vistagen Therapeutics Inc. stock price move sharply2x Return Forecast - Newser
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat
Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru
How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan
Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN
15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey
Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria
Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus
Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com
William Blair Issues Negative Forecast for VTGN Earnings - Defense World
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey
William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat
Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World
Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada
Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo News Canada
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise
Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.91%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):